Journal of Clinical Oncology, Vol 13, 1922-1932, Copyright © 1995 by American Society of Clinical Oncology

ARTICLES

Subsets of CD34+ cells and rapid hematopoietic recovery after peripheral-blood stem-cell transplantation

MW Dercksen, S Rodenhuis, MK Dirkson, WP Schaasberg, JW Baars, E van der Wall, IC Slaper-Cortenbach, HM Pinedo, AE Von dem Borne and CE van der Schoot
European Cancer Centre; Department of Medical Oncology, Free University Hospital, Amsterdam, The Netherlands.

PURPOSE: To study whether there is a relationship between transplanted cell dose and rate of hematopoietic recovery after peripheral-blood stem-cell (PBSC) transplantation, and to obtain an indication whether specific subsets of CD34+ cell populations contribute to rapid recovery of neutrophils or platelets. PATIENTS AND METHODS: Based on data from 59 patients, we calculated for each day after PBSC transplantation the dose of CD34+ cells that resulted in rapid recovery of either neutrophils or platelets in the majority (> 70%) of patients. Using dual-color flow cytometry, subsets of peripheral-blood CD34+ cells were quantified and the numbers of CD34+ cells belonging to each of the reinfused subsets correlated with hematopoietic recovery following high- dose chemotherapy. RESULTS: The calculated threshold values with a high probability of engraftment showed a steep dose-effect relationship between CD34+ cell dose and time to recovery of both neutrophils or platelets. Predominantly CD34+ cells with the phenotype of myeloid precursors were mobilized. A minority of CD34+ cells expressed the erythroid and megakaryocytic lineage-associated antigens and a low but distinct population of CD34+ cells expressed antigens associated with multipotent stem cells. Analysis showed that the number of CD34+CD33- cells (r = -.74, P < .05), as well as the number of CD34+CD41+ cells (r = -.81, P < .005), correlated significantly better with time to neutrophil and platelet recovery, respectively, than with the total number of CD34+ cells (r = -.55 and r = -.56, respectively). CONCLUSION: The numbers of CD34+CD33- cells and CD34+CD41+ cells may help to predict short-term repopulation capacity of PBSCs, especially when relatively low numbers of CD34+ cells per kilogram are reinfused.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				E. Ashihara, C. Shimazaki, A. Okano, M. Hatsuse, A. Okamoto, K. Shimura, R. Takahashi, T. Sumikuma, T. Inaba, N. Fujita, et al. Infusion of a High Number of CD34+ Cells Provides a Rapid Hematopoietic Recovery and Cost Savings in Autologous Peripheral Blood Stem Cell Transplantation Jpn. J. Clin. Oncol., April 1, 2002; 32(4): 135 - 139. [Abstract] [Full Text] [PDF]

				U. Narayanasami, R. Kanteti, J. Morelli, A. Klekar, A. Al-Olama, C. Keating, C. O'Connor, E. Berkman, J. K. Erban, K. A. Sprague, et al. Randomized trial of filgrastim versus chemotherapy and filgrastim mobilization of hematopoietic progenitor cells for rescue in autologous transplantation Blood, October 1, 2001; 98(7): 2059 - 2064. [Abstract] [Full Text] [PDF]

				C. Voermans, M. L. K. Kooi, S. Rodenhuis, H. van der Lelie, C. E. van der Schoot, and W. R. Gerritsen In vitro migratory capacity of CD34+ cells is related to hematopoietic recovery after autologous stem cell transplantation Blood, February 1, 2001; 97(3): 799 - 804. [Abstract] [Full Text] [PDF]

				S. Siena, R. Schiavo, P. Pedrazzoli, and C. Carlo-Stella Therapeutic Relevance of CD34 Cell Dose in Blood Cell Transplantation for Cancer Therapy J. Clin. Oncol., March 13, 2000; 18(6): 1360 - 1377. [Abstract] [Full Text] [PDF]

				R. K. Burt Clinical Utility in Maximizing CD34+ Cell Count in Stem Cell Grafts Oncologist, June 1, 1999; 4(3): 265 - 268. [Full Text]

				E. J. Shpall, C. A. Wheeler, S. A. Turner, S. Yanovich, R. A. Brown, A. L. Pecora, T. C. Shea, K. F. Mangan, S. F. Williams, C. F. LeMaistre, et al. A Randomized Phase 3 Study of Peripheral Blood Progenitor Cell Mobilization With Stem Cell Factor and Filgrastim in High-Risk Breast Cancer Patients Blood, April 15, 1999; 93(8): 2491 - 2501. [Abstract] [Full Text] [PDF]

				C. Bomberger, M. Singh-Jairam, G. Rodey, A. Guerriero, A. M. Yeager, W. H. Fleming, H. K. Holland, and E. K. Waller Lymphoid Reconstitution After Autologous PBSC Transplantation With FACS-Sorted CD34+ Hematopoietic Progenitors Blood, April 1, 1998; 91(7): 2588 - 2600. [Abstract] [Full Text] [PDF]